Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New AF Ablation Tools Offer Promise Of Greater Efficacy, Durability

Executive Summary

Novel arrhythmia mapping technologies, once they are clinically proven and validated, could change practice paradigms in the atrial fibrillation ablation space but in the meantime work continues on nearer-term advances that could make AF ablation more effective and durable. Three of the most promising – contact force sensing, endoscopic laser ablation, and atrial fibrosis imaging, from such companies as Endosense, Biosense Webster, CardioFocus, and Marrek – have recently achieved some important milestones in their journeys toward US market approval.

You may also be interested in...

AF Ablation Procedures Driving CRM Market Expansion

Cardiac rhythm management device sales in the US are projected to grow at a compound annual rate of 2.9%, increasing to an estimated $8.2 billion in the year 2019. Two of the fastest growing sectors of the market, electrophysiology and ablation devices, will be driven by a 10% to 20% growth in the number of patients treated for atrial fibrillation.

Arrhythmia Monitoring: The Challenges Of Detecting AF In Cryptogenic Stroke

Innovation in arrhythmia monitoring technologies, as well as new research showing how these devices may improve arrhythmia diagnosis and management, particularly in cryptogenic stroke patients, will help drive growth in the market for outpatient ambulatory cardiac monitoring devices, which is valued at approximately $1.5 billion in the US alone.

nContact’s Hybrid Convergent Procedure Takes Aim At Persistent AF

Positive clinical results were presented at this year’s Boston AF Symposium on nContact Surgical Inc.’s minimally invasive Convergent Procedure, a combined epicardial and endocardial approach for treating patients with persistent atrial fibrillation, who currently have no good treatment options outside of open surgery. According to the company, about 50% of the entire AF population could potentially benefit from the Convergent Procedure, representing a potential patient market of nearly $15 billion.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts